This company has been marked as potentially delisted and may not be actively trading. bluebird bio (BLUE) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for BLUE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for bluebird bio and its competitors. Enter your email to sign up for newsletter Sign Up BLUE Analyst Ratings Over TimeTypeCurrent Forecast8/2/24 to 8/2/251 Month Ago7/3/24 to 7/3/253 Months Ago5/4/24 to 5/4/251 Year Ago8/3/23 to 8/2/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)2 Buy rating(s)2 Buy rating(s)3 Buy rating(s)Hold6 Hold rating(s)6 Hold rating(s)6 Hold rating(s)6 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)Consensus Price Target$44.60$44.60$44.60$109.25Forecasted Upside797.38% Upside797.38% Upside1,029.11% Upside392.12% UpsideConsensus RatingHoldHoldHoldHold BLUE Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BLUE Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table bluebird bio Stock vs. The CompetitionTypebluebird bioMedical CompaniesS&P 500Consensus Rating Score 2.25 2.81 2.53Consensus RatingHoldModerate BuyModerate BuyPredicted Upside797.38% Upside10,285.39% Upside14.62% UpsideNews Sentiment RatingNeutral NewsSee Recent BLUE NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails3/31/2025Barclays3 of 5 starsGena WangSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetOverweight ➝ Overweight$40.00 ➝ $8.00+56.86%2/24/2025Wells Fargo & Company3 of 5 starsYanan ZhuSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetEqual Weight ➝ Equal Weight$40.00 ➝ $5.00+33.87%2/24/2025JPMorgan Chase & Co.2 of 5 starsEric JosephSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Neutral2/21/2025Baird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. AllenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold11/15/2024Royal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingSector Perform ➝ Sector Perform$80.00 ➝ $80.00+1,142.62%11/15/2024Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeBuy ➝ Neutral$60.00 ➝ $10.00+37.89%9/16/2024Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingNeutral8/15/2024Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOutperform ➝ Outperform$140.00 ➝ $120.00+636.29%3/19/2024WedbushSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral ➝ Neutral$34.40 ➝ $33.60+16.67%3/5/2024HSBCSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetReduce ➝ Reduce$46.20 ➝ $20.40-33.33% Get the Latest News and Ratings for BLUE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. 1/9/2024William BlairSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingMarket Perform12/8/2023Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeUnderweight ➝ Equal Weight$60.00 ➝ $140.00+45.53%11/8/2023Raymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOutperform ➝ Outperform$200.00 ➝ $260.00+267.23%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:59 AM ET. BLUE Forecast - Frequently Asked Questions What is bluebird bio's forecast for 2025? According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for bluebird bio is $44.60, with a high forecast of $120.00 and a low forecast of $5.00. Should I buy or sell bluebird bio stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. Does bluebird bio's stock price have much upside? According to analysts, bluebird bio's stock has a predicted upside of 797.38% based on their 12-month stock forecasts. Do Wall Street analysts like bluebird bio more than its competitors? Analysts like bluebird bio less than other "medical" companies. The consensus rating for bluebird bio is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BLUE compares to other companies. Stock Forecasts and Research Tools Related Companies Galectin Therapeutics Stock Forecast Eledon Pharmaceuticals Stock Forecast CytomX Therapeutics Stock Forecast Kyverna Therapeutics Stock Forecast enGene Stock Forecast Cybin Stock Forecast Aclaris Therapeutics Stock Forecast Voyager Therapeutics Stock Forecast Journey Medical Stock Forecast SELLAS Life Sciences Group Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:BLUE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLUE Stock Alerts